Related Experiment Video
Updated: May 28, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
The association between different monocyte subsets and coronary collateral development
Uğur Arslan1, İbrahim Kocaoğlu, Mesude Yılmaz Falay
1Department of Cardiology, Türkiye Yüksek İhtisas Education and Research Hospital, Ankara, Turkey. ugurarslan5@yahoo.com
Insights
Increased CD14++CD16- monocytes are linked to better coronary collateral development in stable coronary artery disease patients. This finding highlights a potential biomarker for assessing collateralization and guiding future research.
Area of Science:
- Cardiovascular Medicine
- Immunology
- Biomarkers
Background:
- Coronary artery disease (CAD) is a leading cause of mortality worldwide.
- Collateral circulation plays a crucial role in mitigating ischemic damage in CAD.
- Previous studies suggest a link between monocyte counts and collateral development.
Purpose of the Study:
- To investigate the association between specific monocyte subsets and coronary collateral development.
- To determine if CD14++CD16- and CD14+CD16+ monocyte levels correlate with good or poor collateralization in CAD patients.
Main Methods:
- A cohort of 105 patients with significant coronary artery stenosis was analyzed.
- Coronary collateral development was assessed using the Cohen-Rentrop grading method.
- Monocyte subsets (CD14++CD16- and CD14+CD16+) were quantified via cytometric analysis.
Main Results:
- Patients with good collateral development had significantly higher overall monocyte counts.
- Circulating CD14++CD16- monocyte levels were markedly elevated in the good collateral group.
- Multivariate analysis confirmed CD14++CD16- monocytes as an independent predictor of good collateralization.
Conclusions:
- This study is the first to demonstrate a significant association between elevated CD14++CD16- monocyte levels and enhanced coronary collateral development.
- CD14++CD16- monocytes may serve as a valuable biomarker for assessing collateral capacity in CAD.
- Further research is warranted to elucidate the precise mechanisms underlying monocyte subset involvement in collateralization.
Objectives:
An increased circulating monocyte count has been found to be related to good collateral development in patients with stable coronary artery disease. Our aim in this study was to determine any possible relationship between the levels of circulating monocyte subsets and coronary collateral development.
Methods:
Patients who had greater than 95% stenosis of at least one major coronary artery in their first coronary angiogram were included consecutively in this study. Collateral development was graded as good and poor according to the Cohen-Rentrop method. Blood samples were subjected to cytometric analysis for the determination of monocyte subsets, CD14++CD16- and CD14+CD16+ monocytes.
Results:
Out of 105 patients, 55 had good and 50 had poor coronary collateral development. When the baseline characteristics were compared, the monocyte count was significantly higher in the good collateral group (517±151 vs. 396±109/mm3, P<0.001). Cytometric analysis indicated that CD14++CD16- levels were significantly higher in the good collateral group (422±147 vs. 298±105/mm3, P<0.001). CD14+CD16+ cells did not differ between groups (80±29 vs. 84±29/mm3, P=0.41). When multivariate analysis was performed, increased CD14++CD16- levels were still significantly associated with good collateral development [odds ratio: 1.009 (1.005-1.014), P<0.001].
Conclusion:
Our present results are the first to show a significant association between increased circulating CD14++CD16- monocyte levels and good coronary collateral development. Further studies are needed to better understand the relationship between different subsets of monocytes and collateralization.
Related Concept Videos
Coronary Artery Disease II: Pathophysiology
Acute Coronary Syndrome III: Diagnostic Studies
Differentiation of Common Myeloid Progenitor Cells
Coronary Artery Disease III: Clinical Manifestations
